Generics study
This article was originally published in The Tan Sheet
Executive Summary
Office of Management & Budget clears FTC request to conduct study on Hatch/Waxman's effects on competition between branded and generic drug manufacturers; OMB approval was not deemed clear-cut, since former Eli Lilly exec Mitch Daniels heads the office. FTC will issue special orders to 30 innovator companies and 70 generics firms questioning impact of Hatch/Waxman's 180-day marketing exclusivity and 30-month stay provisions on innovation; firms must reply within 60 days. Study was first proposed last fall (1"The Tan Sheet" Oct. 16, 2000, p. 13)You may also be interested in...
Generic Reform Hearings Set In Senate, But McCain/Schumer Lacks Vehicle
Sen. Edward Kennedy (D-Mass.) has committed to generic drug reform hearings in the Health Committee this spring, Capitol Hill staffer Missy Rohrbach told the Generic Pharmaceutical Association annual meeting in Coral Gables, Fla. April 9
Generic Reform Hearings Set In Senate, But McCain/Schumer Lacks Vehicle
Sen. Edward Kennedy (D-Mass.) has committed to generic drug reform hearings in the Health Committee this spring, Capitol Hill staffer Missy Rohrbach told the Generic Pharmaceutical Association annual meeting in Coral Gables, Fla. April 9
Generic Reform Hearings Set In Senate, But McCain/Schumer Lacks Vehicle
Sen. Edward Kennedy (D-Mass.) has committed to generic drug reform hearings in the Health Committee this spring, Capitol Hill staffer Missy Rohrbach told the Generic Pharmaceutical Association annual meeting in Coral Gables, Fla. April 9
Existing Subscriber?
Sign in to continue reading.
Need a specific report? 1000+ reports available
Buy Reports
Need a specific report? 1000+ reports available
Buy Reports
New to Pink Sheet?
Start a free trial today!
Register for our free email digests:
Register for our free email digests: